James J Driscoll
Overview
Explore the profile of James J Driscoll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
919
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Senigarapu S, Driscoll J
Front Med (Lausanne)
. 2024 Nov;
11:1477988.
PMID: 39540049
Cardiac amyloidosis (CA) is a serious condition that results in infiltrative cardiomyopathy and heart failure with preserved ejection fraction (HFpEF) that is caused by the extracellular deposition of amyloid fibrils...
2.
Rana P, Ignatz-Hoover J, Guo C, Mosley A, Malek E, Federov Y, et al.
Mol Cancer Ther
. 2024 Aug;
23(12):1743-1760.
PMID: 39210605
Proteasomes generate antigenic peptides that are presented on the tumor surface to cytotoxic T-lymphocytes. Immunoproteasomes are highly specialized proteasome variants that are expressed at higher levels in antigen-presenting cells and...
3.
Malek E, Rana P, Swamydas M, Daunov M, Miyagi M, Murphy E, et al.
Nat Commun
. 2024 Aug;
15(1):7388.
PMID: 39191755
Functional blockade of the transforming growth factor-beta (TGFβ) signalling pathway improves the efficacy of cytotoxic and immunotherapies. Here, we conducted a phase 1b study (ClinicalTrials.gov., NCT03143985) to determine the primary...
4.
Rana P, Ignatz-Hoover J, Kim B, Malek E, Federov Y, Adams D, et al.
Cancer Res Commun
. 2024 May;
4(6):1517-1532.
PMID: 38747592
Significance: The elimination of therapy-resistant tumor cells remains a major challenge in the treatment of multiple myeloma. Our study identifies and functionally validates agents that amplify MHC class I-presented antigens...
5.
Rana P, Ignatz-Hoover J, Driscoll J
Cancers (Basel)
. 2023 Dec;
15(23).
PMID: 38067336
The majority of T-cell responses involve proteasome-dependent protein degradation and the downstream presentation of oligopeptide products complexed with major histocompatibility complex (MHC) class I (MHC-I) molecules to peptide-restricted CD8 T-cells....
6.
Rani B, Ignatz-Hoover J, Rana P, Driscoll J
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835580
Urothelial cell carcinoma (UCC, bladder cancer, BC) remains a difficult-to-treat malignancy with a rising incidence worldwide. In the U.S., UCC is the sixth most incident neoplasm and ~90% of diagnoses...
7.
Malek E, Wang G, Tatsuoka C, Cullen J, Madabhushi A, Driscoll J
JCO Clin Cancer Inform
. 2023 Sep;
7:e2300078.
PMID: 37738540
Purpose: The gold standard for monitoring response status in patients with multiple myeloma (MM) is serum and urine protein electrophoresis which quantify M-spike proteins; however, the turnaround time for results...
8.
Malek E, Rana P, Swamydas M, Daunov M, Miyagi M, Murphy E, et al.
Res Sq
. 2023 Jul;
PMID: 37503043
Functional blockade of the transforming growth factor-beta (TGF-β) signaling pathway improves the efficacy of cytotoxic and immunotherapies. We conducted a phase 1b study to determine the safety, efficacy, and maximal...
9.
Rana P, Goparaju K, Driscoll J
Front Oncol
. 2023 Jun;
13:1141851.
PMID: 37361580
Pathways that govern cellular bioenergetics are deregulated in tumor cells and represent a hallmark of cancer. Tumor cells have the capacity to reprogram pathways that control nutrient acquisition, anabolism and...
10.
Driscoll J, Ignatz-Hoover J
Oncology (Williston Park)
. 2023 Apr;
37(4):166-167.
PMID: 37104759
No abstract available.